• 締切済み
  • 困ってます

dose-ranging

evaluated in phase II subcutaneous (SC) dose-ranging and intravenous (IV) regimen-finding studies dose-ranging regimen-finding studies 2つの単語に注意して訳してもらえますか?

共感・応援の気持ちを伝えよう!

  • 回答数1
  • 閲覧数162
  • ありがとう数12

みんなの回答

  • 回答No.1
  • SPS700
  • ベストアンサー率46% (14917/31783)

    第2期の皮下投与量の範囲ならびに点滴療法発見の調査によって評定された

共感・感謝の気持ちを伝えよう!

質問者からの補足

これはひどい訳ですね。グーグル翻訳かなにかですか? ひどすぎる。。。

関連するQ&A

  • 2つの単語に注意して訳してもらえますか?

    dose-ranging evaluated in phase II subcutaneous (SC) dose-ranging and intravenous (IV) regimen-finding studies dose-ranging regimen-finding studies 2つの単語に注意して訳してもらえますか?

  • mgの前につく゜ってどういう意味ですか?

    薬学関連にお詳しい方にお伺いしたいと存じます。現在、毒性試験報告書を訳しているのですが、In mice, the maximum non-lethal dose following intravenous administration was 20゜mg/kg (males and females). という文章が出てきて、既に文章全体の意味は把握出来ているものの、mgの前についている゜の意味だけがわからず、これを訳出すべきか否かで困惑しています。゜の意味を教えてください。よろしくお願い致します。

  • 英訳してください

    Clinical trial Before a new drug candidate can proceed to toxicologic or clinical evaluation, considerable analytical chemical development is required to lay the ground work for quality control and stability studies. Drug standards are established and analytical methods for the bulk drug and for the proposed final product are devised. Tentative chemical, physical, and biological specifications of the candidate drug are established. If a compound has desirable activity in an experimental testing system, and appears to be safe upon toxicologic examination, it becomes a candidate for clinical trial. The first trial of a drug in man is done with great caution and on a very limited basis. This study, called Phase I, is devoted primary to ascertaining the safety in the human. When these limits have been established and are found acceptable, the drug is made available to a large number of practicing specialists for the Phase II study, which is principally concerned with the determination of efficacy in patients. If, after Phase II, the drug still looks promising, it is distributed more widely to selected practicing physicians in the Phase III study. The purpose at this stage is to secure data from large number of patients on efficacy and incidence of side effects.

  • Xバー理論?

    i. the boy and the girl who Mary saw ii. a boy and a girl with long hair この2つの文章はXバー理論を説明できますか? もし説明できないならば、なぜ説明できないのか教えてください>< また、Xバー理論で説明できない場合、付属している単語がどうやってくっついているのか 教えてください。

  • 英訳できません

    理系の文献を読んでいたところ訳せない文が出てきて困っています。 For example, it may be instructive to investigate temporal and spatial variations in dielectic permittivity, electrical resistivity / phase and biogeochemical characteristic associated with plumes originating from free product LNAPL sources in granular sediments. まずpermittivityと言う単語が辞書に載っておらずどうしようもありません。 文中のスラッシュ(/)はどういう意味もわかりません。 free product LNAPL sourcesが何なのかもよくわかりません。 associated withは・・・に関連すると訳してよいのでしょうか? どなたかよろしくおねがいします。

  • この英文の和訳をお願いします。

         We evaluated <P(e, 0)> for 12 cases of e between 0 and 6: e=0.0, 0.01, 0.1, 0.5, 0.75, 0.9, 1.0, 1.2, 1.5, 2.0, 4.0, and 6.0. As for r_p, we considered three cases: r_p=0.005, 0.001, and 0.0002. These are representative values of radii of protoplanets at the Earth, Jupiter, and Neptune orbits regions, respectively. The numbers of collision orbits found by our orbital calculation are shown in Table 3 for representative values of e. From Table 3 we can expect the statistical errors in the evaluated collisional rate to be within 5% for the cases of e≦1.5 and within 8% for e=4 and 6; they are smaller than that of the previous studies by Nishida (1983) and by Wetherill and Cox (1985).    The calculated collisional rate is summarized in terms of the enhancement factor defined by Eq. (27) and shown in Fig.11, as a function of e and r_p. From Fig.11 one can see that the collisional rate is always enhanced by the effect of solar gravity, compared with that of the two-body approximation <P(e,0)>_2B. In particular, in regions where e≦1, R(e,0) is almost independent of e, having a value as large as 3. At e≦1, R(e,0) has a notable peak beyond which the enhancement factor decreases gradually with increasing e. For large values of e, i.e., e≧4, <P(e,0)> tends rapidly to <P(e,0)>_2B. As seen in the next section, we will find a similar dependence on e even in the three-dimensional case (i≠0) as long as we are concerned with cases where i≦2. お手数ですが、よろしくお願いします。

  • この文章の和訳をよろしくお願いします。

    Figure 8 shows r_min in the second encounter for b=2.8. In this case, there are four zones of close-encounter orbit in the τ-ω diagram. Comparing Fig.8 with Fig. 7b, the total area occupied by the recurrent close-encounter orbits (the dotted regions in Fig. 8) is smaller than that in the first encounter but not small enough to be neglected. Collision orbits belong necessarily to close-encounter orbits. Consequently, to find collision orbits, we subdivided the τ-ω phase space of close-encounter orbits (i.e., the finely dotted regions in Fig.7) more densely (mesh width being as small as 0.002π in τ) and pursued orbits for each set of τ and ω. Furthermore, as the phase volume of τ and ω occupied by collision orbits, we evaluated a “differential” collisional rate <p(e, i, b)> given by <p(e, i, b)>=(1/(2π)^2)∫p_col (e, i, b, τ, ω)dτdω.      (24) Here, we calculated <p(e, i, b)> separately for 1-, 2-, and more recurrent orbits. The results are shown in Fig. 9, from which we can see that 2-recurrent collision orbits exist for relatively large b, and n-current (n≧3) ones exist only for b≒b_max. That is, the recurrent collision orbits appear only in cases of relatively low energy. From Eq. (10), we have <P(e, i)>=∫【-∞→∞】(3/2)|b|<p(e, i, b)>db.         (25) Using evaluated values of <p(e, i, b)> for various b, we finally obtain <P(e, i)>=0.114 for (e, i)=(1.0, 0.5); the contribution of 2-recurrent orbits is 5%, and that of 3- and more-recurrent orbits is less than 1%. For this case (e=1.0 and i=0.5), we observed 874 collision orbits. The statistical error in evaluating <P(e, i)> is therefore presumed to be of the order of 4%. Since the contribution of 3- and more-recurrent orbits is within the statistical fluctuation, it can be neglected. よろしくお願いします。

  • VOAの記事より

    英語やり直し組みです China faces wide-ranging problems arising from its rapid economic development such as corruption, pollution, high prices and land disputes. (1)itsの必要性がよくわかりません。 「中国は不正や汚染、値段の高騰などその急激な経済成長から起きているwide-ranging問題に直面している」 というような意味だと思うのですが、itsは必要なのでしょうか? また、ないと意味としてわかりにくいorわからないのでしょうか? (2)arisingという単語が使われていますが、resulting from…,occuring from…,causing,などでも代用は可能でしょうか? Li says there have been in his words, "bad incidents", arising from China's development. But he said they are regional and individual in nature. (3)意味がよくわかりません。 「リーは言う、彼の言葉『悪い出来事』(中国の発達から生じている)の中にあった」 in his wordsが良くわからないのですが、これを挿入句?のようにすると「リーはその言葉(話す内容?)の中で、中国の開発から生じている悪い出来事はずっとあった、と言う」 意味はわかるのですが、これだと"の意味がわからないです。 in his words, "bad incidents"これを見る限りwords=bad incidentsのように見えます。。。しかしそう考えると「彼の言葉悪い出来事の中に」となってしまし全体の意味が見えてきません。。。 お願いします。

  • 医療系論文の和訳の添削

    医学的な言い回しも自信がありません。添削お願いします。 Dosage and administration Before use (&#8804;2 hours before administration), one vial of the investigational drug should be dissolved in exactly 5 mL of physiological saline, and one dose should be accurately taken from the solution according to the weight-dose conversion table, based on the subject’s body weight at enrollment (rounded to the nearest kilogram). The dose should be diluted in 100 mL of physiological saline, and administered by continuous intravenous infusion over 2 hours with an infusion pump. 用量・投与 使用前(投与する2時間前)に1バイアルの治験薬を5mlの生理食塩液に溶解する。 1ドースは被験者の登録時の体重(端数は四捨五入)を基にthe weight-dose 投与量換算表(?)により算出された量を計る。ドースは100mlの生理食塩液で希釈し、注入ポンプを用いて2時間以上かけて持続静脈注入する。 Patient enrollment (1) The Principal Investigator or Clinical Investigator shall obtain informed consent from potential subjects and perform the examinations necessary to assess eligibility. (2) The Clinical Investigator shall make the necessary entries in the Case Registration Form and send it to the Data Center by fax. 患者の登録 (1)治験責任医師または治験担当医師は潜在被験者からインフォームドコンセントを受け取り、適正判断に必要な検査を実施する。 (2)治験担当医師は、ケースレジストレーションフォームに必要事項を記載し、データセンターへFAXにて送付する。 よろしくお願いします。

  •  「dose」

     否定・疑問、以外での、「dose」の使い方を教えて下さい。                    He does his work well             彼は自分の仕事を上手くやります                       よろしくお願いします。